Has Anamorelin been officially launched in China?

Anamorelin（Anamorelin） has not been officially approved for marketing in mainland China. The drug was developed by Japan's Ono Pharmaceutical Company, with the trade name Adlumiz. It was approved in Japan in 2021 for the treatment of cancer-related cachexia, and is especially suitable for patients with non-small cell lung cancer, gastric cancer, pancreatic cancer and colorectal cancer. Anamorelin is an oral, selective ghrelin receptor agonist that improves patients' quality of life by simulating the effects of endogenous ghrelin by promoting appetite, increasing weight, and improving muscle mass.

Although anamorelin has been approved in Japan and other countries, it is still in the clinical research stage in mainland China and has not yet been approved by the National Medical Products Administration (NMPA). Therefore, domestic patients cannot purchase the drug through formal channels. Some patients may obtain Anamorelin through international medical channels or cross-border drug purchase channels, but this usually requires the guidance and supervision of professional doctors. It should be noted that there are quality and safety risks in purchasing drugs through informal channels, and patients should choose carefully.

The marketing progress of anamorelin is affected by many factors, including clinical trial data, drug approval process and market demand. Overseas, clinical trial results show that anamorelin has a significant effect on cachexia in patients with non-small cell lung cancer, has fewer side effects, and is well tolerated. These data lay a certain foundation for its promotion in China. As the domestic pharmaceutical market continues to open up, it may only be a matter of time before Anamorelin is launched in China. Once approved, it will provide more treatment options for domestic cancer cachexia patients, reduce their financial burden, and improve their quality of life.

In summary, anamorelin, as a new cancer cachexia treatment drug, has achieved significant therapeutic effects worldwide.

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC4677053/